Pipeline comparison: new entrant vs. established players
Active clinical programmes only (Ph.1 – Ph.3); excludes commercial & registration. Data verified May 2026.
61
total active clinical programmes
8
companies tracked
3
Lilly programmes (3 acquisitions)
0
Lilly Ph.3 assets (for now)
Active clinical programmes by phase
Moderna
23.0% of total
383
14
Sanofi Pasteur
19.7% of total
543
12
GSK
16.4% of total
2242
10
Pfizer
16.4% of total
325
10
BioNTECH SE
13.1% of total
422
8
Merck & Co
4.9% of total
12
3
Eli Lilly†
4.9% of total
21
3
AZ (Icosavax)
1.6% of total
1
1
Phase 1 / Ph.1-readyPhase 1/2Phase 2Phase 3
† New entrant: all Lilly programmes acquired via M&A — Curevo, LimmaTech, Vaccine Company.
Key observations
Lilly enters via bolt-on M&A
All three Lilly programmes were acquired in 2026: Curevo (VZV, Phase 2), LimmaTech (S. aureus, Phase 1), and Vaccine Company (EBV, Phase 1-ready). Zero internal discovery spend required to build the pipeline. The buy-not-build pattern mirrors Lilly's broader business-development posture across other modalities.
Pre-Phase 3 skew signals option-value strategy
Lilly holds no Phase 3 vaccine assets. Contrast Pfizer's 5 Phase 3 programmes or Moderna's 3 Phase 3 plus 8 Phase 2. Lilly retains flexibility to accelerate any single asset, partner on others, or divest — characteristic of an early-portfolio incubator stance rather than a commercial launch posture.
Incumbents command 85% of tracked pipeline volume
The top five incumbents (Moderna, Sanofi Pasteur, GSK, Pfizer, BioNTECH) account for 54 of 61 active programmes — 85.2%. Lilly's 4.9% share is identical to Merck's, but the trajectory matters: a multi-billion-dollar buyer with no legacy vaccine franchise is a different competitive presence than a legacy player thinning its portfolio.
This summary explains what VacZine Analytics Ltd (the data controller) collects when you use this website and the form on this page. The full Privacy Notice is available as a PDF in the footer.
What we collect
If you submit the request form: name, work email, organisation, topic and role indicators, and the IP/User-Agent of your submission. If you accept analytics cookies: aggregate page-visit data via Google Analytics (IP anonymised).
Lawful basis
Consent (UK GDPR Art. 6(1)(a)) for form submissions and any non-essential cookies. Legitimate interest for our own server logs and security monitoring.
Retention
Form submissions are retained for as long as is necessary to fulfil your request and then for up to 24 months for follow-up, unless you ask us to delete sooner.
Your rights
You have rights of access, rectification, erasure, restriction, portability and objection. To exercise any of these, email [email protected]. You may also complain to the UK Information Commissioner's Office (ico.org.uk).
Sharing
We do not sell personal data. Limited processors (email infrastructure, analytics if accepted) handle data on our behalf under written agreements.
Cookie policy
We group cookies and similar technologies into three categories. You control the latter two via the cookie banner (which you can reopen from the footer).
Strictly necessary
Required to run the site. They cannot be disabled. Examples: session integrity, your saved cookie preferences (va.consent.v1 in localStorage).
Analytics (opt-in)
Used only if you accept. Helps us understand which content is read. Example: Google Analytics 4 with IP anonymisation. No personal profiling.
Marketing (opt-in)
Used only if you accept. Measures campaign performance and may enable live-chat widgets. Disabled by default.
Managing your choice
Use the link in the footer at any time. Browser-level controls (e.g. clearing site data) also work.
Terms of use — summary
Use of this website is subject to these terms (in summary) and to our master terms and conditions of business, available as a PDF in the footer for client engagements.
Content on this site is for general information only and does not constitute investment, medical, regulatory, or legal advice. Decisions should be taken with appropriate qualified counsel.
Third-party marks
Product names, trial identifiers, and trademarks shown belong to their respective owners and are used for identification and analytical commentary only.
Governing law
These terms are governed by the laws of England & Wales and subject to the exclusive jurisdiction of the English courts.
Accessibility statement
We're working to make this site usable for the widest possible audience. The current build aims for WCAG 2.1 AA conformance and includes: a skip-to-content link, visible focus styles, semantic landmarks, ARIA labels on interactive controls, sufficient colour contrast against the brand palette, and keyboard operability throughout.
If you encounter a barrier — anything that prevents you from reading or interacting with content — please email [email protected] and we'll address it in our next deploy.
Continuous improvement
We are committed to continuously improving accessibility. If you encounter a barrier — anything that prevents you from reading or interacting with our content — please get in touch and we'll address it in our next deploy. Some decorative SVGs may not yet carry full alt-text equivalents; we treat these as bugs to be fixed as we identify them. Live-chat (if marketing consent is given) is provided by a third party with their own accessibility statement.
Legal Notice & Imprint
Mandatory disclosure of the organisation responsible for this website, in accordance with applicable UK and EU regulations.
Responsible organisation
Legal name: Assay Advantage (VacZine Analytics) Ltd Trading names: Gene Scope Intelligence & VacZine Analytics Registered address: Warren House, Bells Hill, Bishops Stortford, Hertfordshire CM23 2NN, England Companies House registration: 5807728 VAT registration: GB 883 5840 84 Country of incorporation: England & Wales
Data protection framework: UK GDPR & Data Protection Act 2018
Supervisory authority (UK): Information Commissioner's Office (ICO) — ico.org.uk
Privacy policy: View Privacy Policy (PDF)
Cookie policy: View Cookie Policy
Disclaimer
The contents of this website have been prepared with reasonable care. However, Assay Advantage (VacZine Analytics) Ltd accepts no liability for the accuracy, completeness, or timeliness of the information provided on www.genescope-intelligence.com or www.vaczine-analytics.com.
All market intelligence reports and data published on these websites are the intellectual property of Assay Advantage (VacZine Analytics) Ltd and are protected by copyright. Reproduction, distribution, or use of any content without prior written consent is prohibited.
This website may contain links to third-party websites. We have no control over the content or privacy practices of those sites and accept no responsibility for them. External links are provided for informational purposes only.
For questions about this legal notice, please contact us at [email protected] or by post to the registered address above.